Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-07, Stock:NVS, The news for the past five days is as follows:
2018-11-29: NEWS1: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS2: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS3: Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma.NEWS4: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS5: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS6: Roche (RHHBY) to Acquire Jecure and Enter the NASH Space.NEWS7: 4 Big Pharma Stocks to Add to Your Portfolio in December.NEWS8: Novartis: EU Approves Gilenya To Treat MS In Children, Adolescents - Quick Facts.NEWS9: Novartis: EU Approves Gilenya To Treat MS In Children, Adolescents - Quick Facts.NEWS10: Novartis (NVS) Receives EC Approval for Neulasta Biosimilar.NEWS11: Novartis (NVS) Receives EC Approval for Neulasta Biosimilar.
2018-11-30: NEWS1: Novartis' Gilenya Approved in EU for Expanded Population.NEWS2: Novartis' Gilenya Approved in EU for Expanded Population.NEWS3: Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar.NEWS4: This Biotech Stock Could Launch Its First CRISPR Drug In 2022.NEWS5: Novartis' Gilenya Approved in EU for Expanded Population.NEWS6: Novartis CEO Has One New Breakthrough Drug: It Costs $4 Million.
2018-12-03: NEWS1: UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients.NEWS2: Novartis SMA treatment could get FDA approval in May.NEWS3: Novartis: FDA Accepted BLA For SMA Type 1 Gene Replacement Therapy ZOLGENSMA.NEWS4: Novartis: FDA Accepted BLA For SMA Type 1 Gene Replacement Therapy ZOLGENSMA.
2018-12-04: NEWS1: Gilead (GILD) Announces Data on CAR T Therapy Candidate.NEWS2: Gilead (GILD) Announces Data on CAR T Therapy Candidate.NEWS3: Incyte (INCY) Announces Positive Data on Jakafi for GVHD.NEWS4: Gilead (GILD) Announces Data on CAR T Therapy Candidate.NEWS5: FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101.NEWS6: FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101.NEWS7: FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101.NEWS8: Glaxo to Sell India's Popular Horlicks Brand to Unilever.NEWS9: Glaxo to Sell India's Popular Horlicks Brand to Unilever.NEWS10: Global Blood Therapeutics' Voxelotor on Faster Approval Path.NEWS11: Global Blood Therapeutics' Voxelotor on Faster Approval Path.NEWS12: Ajovy Is a New Growth Driver for Teva Pharmaceutical.NEWS13: Global Blood Therapeutics' Voxelotor on Faster Approval Path.NEWS14: Glaxo to Sell India's Popular Horlicks Brand to Unilever.NEWS15: Novartis's new treatment for hives outperforms Xolair in trials.
2018-12-06: NEWS1: Roche's Kadcyla Halves Death Risk in Breast Cancer Study.NEWS2: Roche's Kadcyla Halves Death Risk in Breast Cancer Study.NEWS3: Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study.NEWS4: Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study.NEWS5: Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study.NEWS6: Roche's Kadcyla Halves Death Risk in Breast Cancer Study.

Answer: Decrease